Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In MiMedx Group, Inc. (MDXG) To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in MiMedx, Inc. (“MiMedx” or the “Company”) (NASDAQ: MDXG) of the April 20, 2015 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against MiMedx and certain executives.
A complaint has been filed in the Southern District of New York on behalf of all persons who purchased MiMedx securities from February 26, 2014 through December 31, 2014, inclusive (the “Class Period”).
The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.
Specifically, the action alleges that throughout the Class Period MiMedx failed to disclose that the Company was in violation of federal regulations by conducting improper marketing and sales practices.
On December 31, 2014, MiMedx announced that it had received a subpoena from the Office of Inspector General of the Department of Health and Human Services regarding the Company’s sales and marketing activities.
Following this news, the Company’s stock declined $1.79 per share, or over 15%, to close at $9.74 per share on January 2, 2015.
If you invested in MiMedx stock or options between February 26, 2014 and December 31, 2014 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding MiMedx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.